share_log

An Overview of Corvus Pharma's Earnings

An Overview of Corvus Pharma's Earnings

Corvus Pharma收入概況
Benzinga ·  11/11 22:01

Corvus Pharma (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.

Corvus Pharma(納斯達克:CRVS)計劃於2024年11月12日星期二發佈最新的季度業績。投資者在公佈之前需要了解的內容如下。

Analysts estimate that Corvus Pharma will report an earnings per share (EPS) of $-0.10.

分析師估計,Corvus Pharma的每股收益(EPS)將達到-0.10美元。

The announcement from Corvus Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

投資者急切期待Corvus Pharma的公告,希望了解是否能超越預期並獲得下一季度的良好指引。

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

值得注意的是,對於新投資者來說,指導可能是股票價格波動的關鍵因素。

Overview of Past Earnings

過去收益的概述

In the previous earnings release, the company beat EPS by $0.05, leading to a 9.67% increase in the share price the following trading session.

在上一次業績公佈中,公司每股收益超出0.05美元,導致股價在接下來的交易日上漲了9.67%。

Here's a look at Corvus Pharma's past performance and the resulting price change:

讓我們回顧一下Corvus Pharma的過往表現及其導致的股價變動:

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate -0.12 -0.11 -0.12 -0.12
EPS Actual -0.07 -0.12 -0.14 -0.12
Price Change % 10.0% -12.0% -6.0% 1.0%
季度 2024年第二季度 Q1 2024 2023年第四季度 2023年第三季度
每股收益預估值 -0.12 -0.11 -0.12 -0.12
每股收益實際值 -0.07 -0.12 -0.14 -0.12
價格變更% 10.0% -12.0% -6.0% 1.0%
bigjpg

Corvus Pharma Share Price Analysis

Corvus Pharma股價分析

Shares of Corvus Pharma were trading at $9.45 as of November 08. Over the last 52-week period, shares are up 538.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

截至11月8日,Corvus Pharma股票交易價爲9.45美元。在過去52周內,股票上漲了538.51%。考慮到這些回報通常是積極的,長期股東在這份業績發佈前應感到滿意。

To track all earnings releases for Corvus Pharma visit their earnings calendar on our site.

要追蹤Corvus Pharma的所有業績發佈,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文是由Benzinga的自動內容引擎生成,並由編輯審核。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論